The current guidelines of the European LeukemiaNet (ELN) recommend two drugs in the post-complete-remission (CR) phase of AML: the FLT3 inhibitor midostaurin (for patients with FLT3-mutated AML) and oral azacitidine (with documented efficacy in older patients) [3]. Here, FLT3 is linked to acute myeloid leukemia.